ClinicalTrials.gg
RecruitingNCT07418775Updated May 19, 2026

Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma

An observational study in Meningioma of Brain, Meningioma and Brain Tumor, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
Largest of 14
3,000 · median 106
Started
2026
with 4 others
Observational
14 of 129
5 open now
Primary completion
2031-01
later than 36 of 37 live
Registered
126th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2026, is one of 14 observational ones, reaches primary completion later than 36 of the 37 other live ones, and was the 126th registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess prevalence and distribution of social and structural determinants of health (SSDH) among meningioma patients.

II. To assess disparities in SSDH among meningioma patients of different races.

OUTLINE: This is an observational study.

Participants will complete a survey and have their medical records reviewed.

03

Conditions studied

  • Meningioma of Brain
  • Meningioma
  • Brain Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult participants receiving care at the University of California, San Francisco who have been diagnosed with meningioma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age
  • Able to speak and read English
  • Diagnosed with a meningioma

Exclusion criteria

Exclusion Criteria:

  • Active psychiatric issues (suicidality, active psychosis, grave disability, etc.)
  • Inability to consent secondary to severe neurologic deficit or psychiatric distress
  • Inability to complete survey secondary to severe neurologic deficit or psychiatric distress
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with Meningioma

    Adult patients who have been diagnosed with a meningioma will be asked to complete a one-time survey, which will take roughly 20 minutes to complete. Participants will also have medical records reviewed to capture additional data relating to the participants medical history.

    Behavioral: Questionnaire · Other: Medical Record Review

Interventions

  • BehavioralQuestionnaire

    A questionnaire will be administered in person or online

  • OtherMedical Record Review

    Medical records will be reviewed for study specific data collection

06

What researchers measure

Primary outcomes

  1. Identifying potential social and structural determinants of health (SSDH)

    The prevalence of SSDH factors such as race and ethnicity, birthplace, relationship status, sexual orientation/gender identity, education level, socio-economic status, access to care, reproductive/menstrual history, health factors and medication use, chemical and radiation exposure, smoking history, and perceived stress for participants with meningioma will be analyzed using multilevel logistic and linear models accounting for geographical clustering.

    Time frame: Up to 5 years

  2. Distribution of social and structural determinants of health

    The distribution of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.

    Time frame: Up to 5 years

  3. Identify disparities in social and structural determinants of health (SSDH)

    Disparities of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2031, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Jan 1, 2031
CompletionEst.
Jan 1, 2032
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07418775
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Jan 16, 2026
Primary completion
Jan 1, 2031 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
May 19, 2026

Study contacts

Zora Arum
Contact
zora.arum2@ucsf.edu
877-827-3222
David Raleigh, MD, PhD
principal investigator · University of California, San Francisco, San Francisco, California 94143

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion